Breaking: Novavax wins narrowed approval for its Covid-19 shot after delay

Competitors from Moderna and Pfizer don't have the same restrictions

Log In    Subscribe BREAKING NEWS   Novavax wins narrowed approval for its Covid-19 shot after delay By Helen Branswell Alastair Grant/AP The FDA has finally approved Novavax's Covid-19 vaccine, but in doing so has placed restrictions on it that its two competitors in the U.S. market do not face.    The FDA missed an April 1 deadline to rule on Novavax's application. It was reported that political appointees in Commissioner Marty Makary's office overrode career staff, who recommended issuing the license.   READ MORE Be the first to know Get instant notifications for the topics and reporters you choose with STAT+ Email Alerts. In Case You Missed It 1   FDA commissioner says new vaccine 'framework' for industry is coming within weeks By Lizzy Lawrence 2   Does the CDC have an acting director? By Helen Branswell 3   How Marty Makary's FDA is embracing a more skeptical view of vaccines By Lizzy Lawrence 4   A running list of senior FDA officials who have left the agency By Lizzy Lawrence Don't miss out on another STAT Investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us